RadioS Cancer Research Results

RadioS, RadioSensitizer: Click to Expand ⟱
Source:
Type:
A radiosensitizer is an agent that makes cancer cells more sensitive to the damaging effects of radiation therapy. By using a radiosensitizer, clinicians aim to enhance the effectiveness of radiation treatment by either increasing the damage incurred by tumor cells or by interfering with the cancer cells’ repair mechanisms. This can potentially allow for lower doses of radiation, reduced side effects, or improved treatment outcomes.
Pathways that help Radiosensitivity: downregulating HIF-1α, increase SIRT1, Txr

List of Natural Products with radiosensitizing properties:
-Curcumin:modulate NF-κB, STAT3 and has been shown in preclinical studies to enhance the effects of radiation by inhibiting cell survival pathways.
-Resveratrol:
-EGCG:
-Quercetin:
-Genistein:
-Parthenolide:

How radiosensitizers inhibit the thioredoxin (Trx) system in cellular contexts. Notable radiosensitizers, including:
-gold nanoparticles (GNPs),
-gold triethylphosphine cyanide ([Au(SCN) (PEt3)]),
-auranofin, ceria nanoparticles (CONPs),
-curcumin and its derivatives,
-piperlongamide,
-indolequinone derivatives,
-micheliolide,
-motexafin gadolinium, and
-ethane selenide selenidazole derivatives (SeDs)
Scientific Papers found: Click to Expand⟱
5148- GamB,    Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics
- Review, Var, NA
AntiCan↑, angioG↓, ChemoSen↑, RadioS↑, VEGF↓, MMP2↓, MMP9↓, Telomerase↓, TrxR↓, ERK↓, HSP90↓, ROS↑, SIRT1↑, survivin↓, cFLIP↓, Casp3↑, Casp8↑, Casp9↑, BAD↓, BID↓, Bcl-2↓, BAX↑, STAT3↓, hTERT/TERT↓, NF-kB↓, Myc↓, Hif1a↓, FOXD3↑, BioAv↓, BioAv↑, P53↑, eff↓, OCR↓, MMP↓, PI3K↓, Akt↓, BBB↑, TumCG↓, TumMeta↓, BioAv↑,
1957- GamB,    Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy
- in-vitro, ESCC, EC9706
AntiCan↑, toxicity↓, TumCP↓, Apoptosis↑, TumCCA↑, MMP↓, ROS↑, eff↓, RadioS↑,
1901- GoldNP,  Rad,    The role of thioredoxin reductase in gold nanoparticle radiosensitization effects
- in-vitro, Lung, A549
MMP↓, ROS↑, RadioS↑, TrxR↓,
4420- GoldNP,  Rad,    Computational modeling and experimental synthesis of BSA-coated bimetallic theranostic MnO₂-Au@curcumin nanoplatform for synergistic radiochemotherapy of breast cancer
- in-vitro, BC, 4T1
RadioS↑,
3526- GoldNP,  Rad,    Advances in nanoparticle-based radiotherapy for cancer treatment
- Review, Var, NA
RadioS↑, EPR↑, ROS↑, TumCCA↑,
1638- HCAs,    Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications
- Review, Nor, NA
*BioAv↓, Inflam↓, COX2↓, TumCCA↑, ChemoSen↑, RadioS↑, selectivity↑, ROS↑, DNAdam↑, antiOx↑, SOD↑, Catalase↑, GPx↑, GSH↑, NRF2↑, NF-kB↓, Cyc↓, CDK1↑, P21↑, p27↑, P53↑, VEGF↓, MAPK↓,
2883- HNK,    Honokiol targets mitochondria to halt cancer progression and metastasis
- Review, Var, NA
ChemoSen↑, BBB↓, Ca+2↑, Cyt‑c↑, Casp3↑, chemoPv↑, OCR↓, mitResp↓, Apoptosis↑, RadioS↑, NF-kB↓, Akt↓, TNF-α↓, PGE2↓, VEGF↓, NO↝, COX2↓, RAS↓, EMT↓, Snail↓, N-cadherin↓, β-catenin/ZEB1↓, E-cadherin↑, ER Stress↑, p‑STAT3↓, EGFR↓, mTOR↓, mt-ROS↑, PI3K↓, Wnt↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
2896- HNK,    Honokiol inhibits hypoxia-inducible factor-1 pathway
- in-vivo, Colon, CT26
Hif1a↓, RadioS↑,
4522- HNK,  MAG,    Honokiol Is More Potent than Magnolol in Reducing Head and Neck Cancer Cell Growth
- in-vitro, HNSCC, FaDu
AntiCan↑, tumCV↓, eff↑, survivin↓, RadioS↑,
5053- HPT,  Rad,  Chemo,    Association of elevated reactive oxygen species and hyperthermia induced radiosensitivity in cancer stem-like cells
- in-vitro, Var, NA
CSCs↓, TumCP↓, ROS↑, RadioS↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2917- LT,  Rad,    Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade
- in-vitro, Lung, NA
Bcl-2↓, Casp3↑, Casp8↑, Casp9↑, p‑p38↑, ROS↑, RadioS↑,
3273- Lyco,    Lycopene
- Review, Var, NA
antiOx↑, ChemoSen↓, RadioS↓,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX↑, P21↑, p27↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
5800- MET,    Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
- Review, Var, NA
ChemoSen↑, RadioS↑, Imm↑, *AntiDiabetic↑, *AMPK↑, TumCP↓, hepatoP↑, ATP↓, AMP↑, glucoNG↓, ROS↑, compI↓, DNAdam↑, CSCs↓, NP/CIPN↓, chemoP↑, toxicity↓, Trx↓, eff↑, cycD1/CCND1↓, CDK4↓, CDK6↓, cycE/CCNE↓, CDK2↓,
2251- MF,  Rad,    BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage
- in-vitro, Lung, A549 - in-vitro, HNSCC, UTSCC15 - in-vitro, CRC, DLD1 - in-vitro, PC, MIA PaCa-2
RadioS↑, DNAdam↑, ROS↑, ChemoSen∅, Pyruv↓, ADP:ATP↓, ROS↑,
2244- MF,    Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer
- Review, Var, NA
RPM↑, Glycolysis∅, ROS↑, ChemoSen↑, RadioS↑, selectivity↑,
3477- MF,    Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis
- Review, NA, NA
*Ca+2↑, *VEGF↑, *angioG↑, Ca+2↑, ROS↑, Necroptosis↑, TumCCA↑, Apoptosis↑, *ATP↑, *FAK↑, *Wnt↑, *β-catenin/ZEB1↑, *ROS↑, p38↑, MAPK↑, β-catenin/ZEB1↓, CSCs↓, TumCP↓, ROS↑, RadioS↑, Ca+2↑, eff↓, NO↑,
512- MF,    Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, FF95
TumCP↓, *toxicity↓, ChemoSen↑, RadioS↑, selectivity↑, Ca+2↑,
5253- NCL,    Niclosamide: Beyond an antihelminthic drug
- Review, Var, NA
TumCP↓, Apoptosis↑, EMT↓, β-catenin/ZEB1↓, TumCG↓, toxicity↓, Wnt↓, LRP6↓, eff↑, DR5↑, mTORC1↓, pH↓, CSCs↓, IL6↓, JAK1↓, STAT3↓, ChemoSen↑, TumCG↓, tumCV↓, NOTCH↓, NF-kB↓, EGFR↓, ROS↑, RadioS↑, cFos↓, cJun↓, E2Fs↓, cMyc↓, Half-Life↓, BioAv↝,
5254- NCL,    The magic bullet: Niclosamide
- Review, Var, NA
Wnt↓, β-catenin/ZEB1↓, RAS↓, STAT3↓, NOTCH↓, E2Fs↓, mTOR↓, eff↑, PD-1↓, PD-L1↓, BioAv↝, toxicity↓, BioAv↑, ETC↑, NADH:NAD↓, TCA↑, Warburg↓, Diff↑, AMPK↑, P53↑, PP2A↑, HIF-1↓, KRAS↓, Myc↓, RadioS↑, ChemoSen↑, Dose↝, Dose↑,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
4627- OLE,    Oleuropein regulates ubiquitination-mediated Mcl-1 turnover and exhibits antitumor activity
- in-vitro, Oral, NA
tumCV↓, Mcl-1↓, TumCG↓, toxicity∅, RadioS↑, AntiTum↑,
1811- Oxy,    Hyperbaric oxygen therapy and cancer—a review
- Review, NA, NA
toxicity∅, AntiTum↑, MAPK↑, ERK↓, ChemoSen↑, ChemoSen↑, RadioS↑,
1813- Oxy,    Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment
- Review, Var, NA
ChemoSen↑, RadioS↑, PD-L1↓, Hif1a↓, ROS↑,
1814- Oxy,    Hyperbaric oxygen therapy for malignancy: a review
- Review, Var, NA
ROS↑, SOD↑, OS↑, ChemoSen↑, RadioS↑, BioAv↑,
2063- PB,  Rad,    Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation
- in-vitro, GBM, U87MG - NA, NA, U251
RadioS↑, eff↝, P53↝,
2064- PB,  Rad,    Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
Bcl-xL↓, Cav1↓, VEGF↓, RadioS↑, chemoP↑, HDAC↓, *toxicity↓, Diff↑, Prot↓,
2066- PB,  Rad,    Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas
- in-vitro, GBM, U251
RadioS↑,
2043- PB,  Cisplatin,    Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
- in-vitro, HNSCC, UM-SCC-1
ChemoSen↑, eff↑, HDAC↓, BRCA1↓, RadioS↑,
1672- PBG,    The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers
- Review, BC, NA
ChemoSen↓, RadioS↑, Inflam↓, AntiCan↑, Dose∅, mtDam↑, Apoptosis?, OCR↓, ATP↓, ROS↑, ROS↑, LDH↓, TP53↓, Casp3↓, BAX↓, P21↓, ROS↑, eNOS↑, iNOS↑, eff↑, hTERT/TERT↓, cycD1/CCND1↓, eff↑, eff↑, eff↑, eff↑, STAT3↓, TIMP1↓, IL4↓, IL10↓, OS↑, Dose∅, ER Stress↑, ROS↑, NF-kB↓, p65↓, MMP↓, TumAuto↑, LC3II↑, p62↓, TLR4↓, mtDam↑, LDH↓, ROS↑, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDH↓, IL10↓, HDAC8↓, eff↑, eff↑, P21↑,
1673- PBG,    An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms
- Review, Var, NA
TumCP↓, Apoptosis↑, TumCCA↑, MALAT1↓, P53↑, RadioS↑, OS↑, ROS↑, NF-kB↓, p65↑, MMP↓, ROS↑, MMP9↓, β-catenin/ZEB1↓, Vim↓, E-cadherin↓, VEGF↓, EMT↓,
1683- PBG,  Rad,    Protective effect of propolis in protecting against radiation-induced oxidative stress in the liver as a distant organ
- in-vivo, Nor, NA
GPx↑, SOD↓, RadioS↑,
1661- PBG,    Propolis: a natural compound with potential as an adjuvant in cancer therapy - a review of signaling pathways
- Review, Var, NA
JNK↓, ERK↓, Akt↓, NF-kB↓, FAK↓, MAPK↓, PI3K↓, Akt↓, P21↑, p27↑, TRAIL↑, BAX↑, P53↑, ERK↓, ChemoSen↑, RadioS↑, Glycolysis↓, HK2↓, PKM2↓, LDHA↓, PFK↓,
1662- PBG,    The immunomodulatory and anticancer properties of propolis
- Review, Var, NA
IL6↓, IL12↓, IL10↑, CSCs↓, PAK1↓, VEGF↓, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, ChemoSen↑, RadioS↑,
1664- PBG,    Anticancer Activity of Propolis and Its Compounds
- Review, Var, NA
Apoptosis↑, TumCMig↓, TumCCA↑, TumCP↓, angioG↓, P21↑, p27↑, CDK1↓, p‑CDK1↓, cycA1/CCNA1↓, CycB/CCNB1↓, P70S6K↓, CLDN2↓, HK2↓, PFK↓, PKM2↓, LDHA↓, TLR4↓, H3↓, α-tubulin↓, ROS↑, Akt↓, GSK‐3β↓, FOXO3↓, NF-kB↓, cycD1/CCND1↓, MMP↓, ROS↑, i-Ca+2↑, lipid-P↑, ER Stress↑, UPR↑, PERK↑, eIF2α↑, GRP78/BiP↑, BAX↑, PUMA↑, ROS↑, MMP↓, Cyt‑c↑, cl‑Casp8↑, cl‑Casp8↑, cl‑Casp3↑, cl‑PARP↑, eff↑, eff↑, RadioS↑, ChemoSen↑, eff↑,
1666- PBG,    Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
- Review, Var, NA
ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1/CCNA1↓, CycB/CCNB1↓, CDK2↓, P21↑, p27↑, hTERT/TERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,
5208- PI,    Piperine Inhibits Cell Proliferation and Induces Apoptosis of Human Gastric Cancer Cells by Downregulating Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway
- in-vitro, GC, SNU16 - in-vitro, Nor, GES-1
TumCP↓, Apoptosis↑, BAX↑, BAD↑, Cyt‑c↑, cl‑PARP↑, cl‑Casp3↑, Bcl-2↓, Bcl-xL↓, p‑PI3K↓, p‑Akt↓, Ki-67↓, toxicity↓, RadioS↑,
2942- PL,    Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems
- in-vitro, CRC, CT26 - in-vitro, CRC, DLD1 - in-vivo, CRC, CT26
ROS↑, GSH↓, TrxR↓, RadioS↑, DNAdam↑, TumCCA↑, mitResp↓, GSTs↓, OS↑,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1/ABCC1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
4968- PSO,    Psoralidin: emerging biological activities of therapeutic benefits and its potential utility in cervical cancer
- in-vitro, Cerv, NA
*Inflam↓, *antiOx↑, *neuroP↑, *AntiDiabetic↑, *Bacteria↓, AntiTum↑, CSCs↓, ROS↑, TumAuto↑, Apoptosis↑, ChemoSen↑, RadioS↑, BioAv↓, *cardioP↑, *ROS↓, *LDH↓, TumCP↓, TRAIL⇅, TumCMig↓, EMT↓, NF-kB↓, P53↑, Casp3↑, NOTCH↓, CSCs↓, angioG↓, VEGF↓, Ki-67↓, CD31↓, TRAILR↑, MMP↓, BioAv↓, BioAv↑,
1985- PTL,    KEAP1 Is a Redox Sensitive Target That Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Nor, PrEC - in-vivo, NA, NA
ROS↑, NADPH↑, RadioS↑, radioP↑, Trx↓, *ox-Keap1↑, ox-Keap1↓, rd-Keap1↑, *NRF2↑, NRF2∅, NF-kB↓,
1987- PTL,  Rad,    A NADPH oxidase dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Nor, PrEC
selectivity↑, RadioS↑, ROS↑, *ROS∅, NADPH↑, Trx↓, PI3K↑, Akt↑, p‑FOXO3↓, SOD2↓, Catalase↓, radioP↑, *NADPH∅, *GSH↑, *GSH/GSSG↑, *NRF2↑,
1983- PTL,    Targeting thioredoxin reductase by micheliolide contributes to radiosensitizing and inducing apoptosis of HeLa cells
- in-vitro, Cerv, HeLa
eff↑, TrxR↓, ROS↑, RadioS↑,
1493- QC,    New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer
- NA, Bladder, NA
RadioS↑, ChemoSen↑,
97- QC,  HPT,    Effects of the flavonoid drug Quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo
- in-vitro, Pca, PC3
HSP72↑, TumCG↓, eff↑, ChemoSen↑, RadioS↑,
5857- RES,  CAP,  Rad,    Resveratrol and capsaicin as safer radiosensitizers for colorectal cancer compared to 5-fluorouracil
- in-vivo, Var, NA
RadioS↑, hepatoP↝, toxicity↓,

Showing Research Papers: 151 to 200 of 243
Prev Page 4 of 5 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 243

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 2,   Catalase↓, 3,   Catalase↑, 1,   compI↓, 1,   CYP1A1↓, 1,   GPx↓, 1,   GPx↑, 2,   GSH↓, 5,   GSH↑, 1,   GSR↓, 1,   GSTs↓, 2,   HO-1↓, 2,   HO-1↑, 2,   ox-Keap1↓, 1,   rd-Keap1↑, 1,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↑, 1,   NOX4↑, 1,   NQO1↓, 1,   NQO1↑, 1,   NRF2↓, 2,   NRF2↑, 4,   NRF2∅, 1,   Prx4↑, 1,   ROS↓, 1,   ROS↑, 37,   ROS⇅, 1,   mt-ROS↑, 1,   RPM↑, 1,   SIRT3↓, 1,   SOD↓, 2,   SOD↑, 3,   SOD1↑, 1,   SOD2↓, 3,   SOD2↑, 1,   Trx↓, 3,   TrxR↓, 6,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↓, 1,   AIF↑, 1,   ATP↓, 2,   CDC2↓, 1,   ETC↑, 1,   mitResp↓, 2,   MMP↓, 9,   mtDam↑, 2,   OCR↓, 3,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMP↑, 1,   AMPK↑, 1,   CAIX↑, 1,   Cav1↓, 1,   cMyc↓, 3,   p‑cMyc↑, 1,   FASN↓, 1,   glucoNG↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 4,   Glycolysis∅, 1,   HK2↓, 6,   lactateProd↓, 1,   LDH↓, 3,   LDHA↓, 2,   NADH:NAD↓, 1,   NADPH↑, 2,   PFK↓, 3,   PKM2↓, 3,   PPARγ↑, 1,   Pyruv↓, 1,   SIRT1↓, 1,   SIRT1↑, 1,   TCA↑, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 10,   Akt↑, 1,   p‑Akt↓, 3,   Apoptosis?, 1,   Apoptosis↑, 11,   BAD↓, 1,   BAD↑, 2,   Bak↑, 1,   BAX↓, 1,   BAX↑, 8,   Bcl-2↓, 7,   Bcl-xL↓, 2,   BID↓, 1,   BIM↑, 1,   Casp1↓, 1,   Casp3↓, 1,   Casp3↑, 10,   cl‑Casp3↑, 3,   Casp7↑, 2,   Casp8↑, 5,   cl‑Casp8↑, 3,   Casp9↑, 6,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 6,   DR5↑, 3,   Fas↑, 1,   FasL↑, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 4,   iNOS↓, 1,   iNOS↑, 1,   JNK↓, 1,   JNK↑, 2,   p‑JNK↑, 1,   MAPK↓, 3,   MAPK↑, 3,   Mcl-1↓, 1,   MDM2↓, 2,   p‑MDM2↓, 1,   Myc↓, 2,   Necroptosis↑, 1,   NICD↓, 1,   p27↑, 6,   p38↑, 1,   p‑p38↑, 2,   PUMA↑, 1,   survivin↓, 5,   Telomerase↓, 2,   TRAIL↑, 1,   TRAIL⇅, 1,   TRAILR↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 1,   FOXD3↑, 1,   p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 3,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   H3↓, 2,   H4↓, 1,   Prot↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 4,   eIF2α↑, 1,   p‑eIF2α↑, 2,   ER Stress↑, 6,   GRP78/BiP↑, 1,   HSP72↑, 1,   HSP90↓, 1,   PERK↑, 1,   UPR↑, 2,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3B-II↑, 1,   LC3II↑, 2,   p62↓, 1,   TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

BRCA1↓, 1,   DNAdam↑, 8,   DNArepair↑, 1,   P53↑, 10,   P53↝, 1,   PARP↑, 2,   cl‑PARP↑, 5,   PCNA↓, 2,   TP53↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK1↑, 1,   p‑CDK1↓, 1,   CDK2↓, 4,   CDK4↓, 5,   Cyc↓, 1,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 5,   cycD1/CCND1↓, 7,   cycE/CCNE↓, 1,   E2Fs↓, 2,   P21↓, 1,   P21↑, 10,   RB1↓, 1,   p‑RB1↓, 1,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD34↓, 1,   cFos↓, 2,   cFos↑, 1,   cMET↓, 1,   CSCs↓, 7,   Diff↑, 2,   EMT↓, 7,   ERK↓, 7,   FOXO3↓, 1,   p‑FOXO3↓, 2,   GSK‐3β↓, 2,   p‑GSK‐3β↓, 1,   HDAC↓, 4,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC8↓, 1,   IGF-1R↓, 1,   LRP6↓, 1,   mTOR↓, 7,   mTORC1↓, 1,   Nanog↓, 1,   NOTCH↓, 3,   NOTCH1↓, 2,   OCT4↓, 1,   P70S6K↓, 1,   PI3K↓, 5,   PI3K↑, 1,   p‑PI3K↓, 2,   PTEN↓, 1,   PTEN↑, 3,   RAS↓, 5,   SOX2↓, 1,   p‑Src↓, 1,   STAT1↓, 1,   STAT3↓, 10,   p‑STAT3↓, 1,   STAT6↓, 1,   p‑STAT6↓, 1,   TAZ↓, 1,   TOP2↓, 1,   TumCG↓, 6,   TumCG↑, 1,   Wnt↓, 4,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   AP-1↓, 1,   AXL↓, 1,   Ca+2↑, 5,   i-Ca+2↑, 1,   CD31↓, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   CLDN2↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 4,   FAK↓, 2,   ITGB1↓, 1,   Ki-67↓, 3,   KRAS↓, 1,   MALAT1↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP13↓, 1,   MMP2↓, 6,   MMP9↓, 7,   MMPs↓, 1,   N-cadherin↓, 4,   PAK1↓, 1,   Rac1↓, 1,   Rho↓, 1,   Slug↓, 1,   Snail↓, 3,   SOX4↑, 1,   TIMP1↓, 1,   TIMP1↑, 1,   TIMP2↑, 1,   Treg lymp↓, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 15,   TumMeta↓, 4,   TumMeta↑, 1,   Twist↓, 2,   Tyro3↓, 1,   Vim↓, 3,   Vim↑, 1,   ZO-1↑, 1,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 7,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 7,   ATF4↑, 1,   ATF4↝, 1,   EGFR↓, 4,   EGFR↑, 1,   eNOS↑, 1,   EPR↑, 1,   HIF-1↓, 1,   Hif1a↓, 7,   LOX1↓, 1,   NO↓, 1,   NO↑, 2,   NO↝, 1,   VEGF↓, 13,   VEGFR2↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↓, 1,   BBB↑, 2,   GLUT1↓, 1,   GLUT1↑, 1,   GLUT3↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   CD4+↑, 1,   COX2↓, 6,   COX2↑, 1,   CXCR4↓, 2,   FOXP3↓, 1,   ICAM-1↓, 2,   IFN-γ↓, 1,   Igs↑, 1,   IKKα↓, 2,   IL10↓, 2,   IL10↑, 1,   IL12↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL4↓, 1,   IL6↓, 7,   IL8↓, 2,   Imm↑, 1,   Inflam↓, 4,   JAK1↓, 3,   JAK2↓, 2,   NF-kB↓, 18,   p‑NF-kB↑, 1,   NK cell↑, 2,   p65↓, 2,   p65↑, 1,   p‑p65↓, 1,   PD-1↓, 2,   PD-L1↓, 2,   PGE2↓, 2,   T-Cell↑, 1,   Th1 response↑, 1,   TLR4↓, 2,   TNF-α↓, 2,   TNF-α↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,   PP2A↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   CDK6↓, 3,   ER(estro)↓, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 7,   BioAv↑, 7,   BioAv↝, 4,   BioEnh↑, 1,   ChemoSen↓, 3,   ChemoSen↑, 27,   ChemoSen∅, 1,   Dose?, 1,   Dose↑, 1,   Dose↝, 1,   Dose∅, 3,   eff↓, 4,   eff↑, 20,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 4,   MDR1↓, 2,   MRP1/ABCC1↓, 1,   RadioS↓, 1,   RadioS↑, 49,   selectivity↑, 8,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   BRCA1↓, 1,   CEA↓, 1,   EGFR↓, 4,   EGFR↑, 1,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 4,   IL6↓, 7,   Ki-67↓, 3,   KRAS↓, 1,   LDH↓, 3,   Myc↓, 2,   NSE↓, 1,   PD-L1↓, 2,   TP53↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 5,   AntiTum↑, 3,   cachexia↓, 1,   cardioP↑, 1,   chemoP↑, 4,   chemoPv↑, 1,   ChemoSideEff↓, 1,   hepatoP↑, 1,   hepatoP↝, 1,   NP/CIPN↓, 1,   OS↑, 5,   radioP↑, 3,   toxicity↓, 8,   toxicity∅, 2,   TumW↓, 1,  
Total Targets: 381

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Catalase↑, 3,   GPx↑, 2,   GSH↑, 5,   GSH/GSSG↑, 1,   GSTs↑, 1,   ox-Keap1↑, 1,   lipid-P↓, 2,   MDA↓, 1,   NRF2↑, 3,   ROS↓, 3,   ROS↑, 1,   ROS∅, 1,   SOD↑, 3,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   LDH↓, 1,   NADPH∅, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Wnt↑, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   FAK↑, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,   VEGF↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL10↑, 1,   IL1β↓, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 1,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 2,   cardioP↑, 1,   chemoP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   toxicity↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 42

Scientific Paper Hit Count for: RadioS, RadioSensitizer
58 Radiotherapy/Radiation
18 Curcumin
10 Silver-NanoParticles
8 Betulinic acid
8 Propolis -bee glue
8 Resveratrol
7 Baicalein
6 Berberine
6 salinomycin
6 diet Methionine-Restricted Diet
6 Ellagic acid
5 Chemotherapy
5 Copper and Cu NanoParticles
5 Dichloroacetate
5 Disulfiram
5 Fisetin
5 Thymoquinone
4 Atorvastatin
4 Cisplatin
4 Chrysin
4 Honokiol
4 Magnetic Fields
4 Phenylbutyrate
4 Sulforaphane (mainly Broccoli)
4 Selenium NanoParticles
4 Selenite (Sodium)
3 Hyperthermia
3 Selenium
3 Apigenin (mainly Parsley)
3 Ashwagandha(Withaferin A)
3 brusatol
3 Crocetin
3 Eugenol
3 diet FMD Fasting Mimicking Diet
3 Gold NanoParticles
3 Luteolin
3 Oxygen, Hyperbaric
3 Piperlongumine
3 Parthenolide
3 Sulfasalazine
2 3-bromopyruvate
2 Auranofin
2 Allicin (mainly Garlic)
2 Anti-oxidants
2 Astaxanthin
2 Beta-Caryophyllene
2 Brucea javanica
2 Caffeic acid
2 Capsaicin
2 Caffeic Acid Phenethyl Ester (CAPE)
2 chemodynamic therapy
2 Celastrol
2 diet Short Term Fasting
2 EGCG (Epigallocatechin Gallate)
2 Ferulic acid
2 Gambogic Acid
2 Niclosamide (Niclocide)
2 Oleuropein
2 Quercetin
2 Rosmarinic acid
2 Silymarin (Milk Thistle) silibinin
2 Vitamin D3
1 2-DeoxyGlucose
1 Astragalus
1 Alpha-Lipoic-Acid
1 Vitamin A, Retinoic Acid
1 Vitamin C (Ascorbic Acid)
1 Artemisinin
1 Aspirin
1 Baicalin
1 Berbamine
1 Biochanin A
1 Bromelain
1 borneol
1 Boron
1 Black phosphorus
1 α-Bisabolol / Chamomile oil
1 Butyrate
1 Zinc
1 Carvacrol
1 Thymol-Thymus vulgaris
1 carboplatin
1 Celecoxib
1 Centella asiatica / Gotu kola → asiaticoside
1 Chlorogenic acid
1 Coenzyme Q10
1 Cucurbitacin
1 Diclofenac
1 immunotherapy
1 Electrical Pulses
1 Hydroxycinnamic-acid
1 Magnolol
1 Lycopene
1 Melatonin
1 Metformin
1 HydroxyTyrosol
1 Piperine
1 Psoralidin
1 Oxaliplatin
1 Shikonin
1 Urolithin
1 Vitamin K2
1 Zerumbone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1107  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page